The affect of goserelin on the QoL of women having chemotherapy for EBC: results from the OPTION trial

Leonard, R, Yellowlees, A, Mansi, J, Fallowfield, L and Jenkins, V (2020) The affect of goserelin on the QoL of women having chemotherapy for EBC: results from the OPTION trial. Breast, 52. pp. 122-131. ISSN 0960-9776

[img] PDF (uncorrected proof) - Other
Restricted to SRO admin only
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (1MB)
[img] PDF - Accepted Version
Restricted to SRO admin only
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (1MB)
[img] PDF - Published Version
Available under License Creative Commons Attribution.

Download (1MB)

Abstract

Background
The OPTION trial results showed that premenopausal women with early stage breast cancer (EBC) receiving chemotherapy benefited from ovarian function protection with goserelin. The impact of treatments on patient reported Quality of Life (QoL) were also examined.

Patients and methods
227 pre-menopausal women with EBC, were randomly assigned to chemotherapy±goserelin (C±G); 132 (58%) were ER-ve. Patients were stratified by age (≤40 years and >40 years). QoL was assessed with the Functional Assessment of Cancer Therapy – Breast, and Endocrine Symptom checklist at baseline (pre-treatment), 3, 6, 12, 18 and 24 months, then annually to 5 years. Treatment Outcome Index (TOI) score was the primary outcome.

Results
213 patients were available for QoL analysis. There was a significant decrease in TOI scores for both treatment groups at 3 and 6 months that returned to pre-treatment levels at 12 months, then continued to increase reflecting improved QoL. By 3 months there was a significant difference from baseline in both groups for menopausal symptoms, and between groups in the proportion experiencing hot flushes at any time. The C + G group experienced higher levels of vasomotor symptoms generally during the treatment phase; by 24 months, the short-term negative effect of goserelin was reversed, with hot flushes twice as frequent in the chemotherapy only group (40.9% vs 21.3%).

Conclusions
These results show that young women diagnosed with breast cancer experienced only a short-term decrease in QoL from the addition of goserelin, in order to preserve ovarian function during chemotherapy treatment.

Item Type: Article
Keywords: OPTION trial, Chemotherapy, Quality of Life, Pre-menopausal, Breast Cancer, Goserelin
Schools and Departments: Brighton and Sussex Medical School > Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
SWORD Depositor: Mx Elements Account
Depositing User: Mx Elements Account
Date Deposited: 03 Jun 2020 07:27
Last Modified: 18 Jun 2020 11:00
URI: http://sro.sussex.ac.uk/id/eprint/91566

View download statistics for this item

📧 Request an update